Niu Chenchen, Ren Dong, Tran Truc, Gamayo Ashley, Rezk Sherif, Zhao Xiaohui
Department of Pathology & Laboratory Medicine, University of California Irvine Medical Center (UCIMC), Orange, CA, USA.
J Pathol Transl Med. 2025 Jul;59(4):262-268. doi: 10.4132/jptm.2025.04.17. Epub 2025 May 15.
The aberrant expression of specific T-cell maker CD3 in B-cell neoplasms can be a potential diagnostic pitfall leading to a misclassification of cell lineage. Here, we report a case of recurrent solitary plasmacytoma with new aberrant expression of CD3. The neoplastic plasma cells of the recurrent tumor were kappa restricted, positive for CD138, MUM1, negative for CD20, cyclin D1, and Epstein-Barr virus. CD79a was positive in majority of the tumor cells, except for a small focus which was strongly positive for CD3, but negative for other T-cell markers (CD2, CD5, CD7, CD4, and CD8) and CD56. The neoplastic plasma cells of the original tumor were negative for CD3. To the best of our knowledge, only one case of recurrent plasmacytoma with aberrant expression of CD3 has been published, which revealed disease progression in the recurrence. However, we did not observe morphologic evidence of disease progression in our case.
B细胞肿瘤中特异性T细胞标志物CD3的异常表达可能成为潜在的诊断陷阱,导致细胞系别分类错误。在此,我们报告一例复发性孤立性浆细胞瘤,其出现了新的CD3异常表达。复发性肿瘤的肿瘤性浆细胞呈κ轻链限制性,CD138、MUM1阳性,CD20、细胞周期蛋白D1和爱泼斯坦-巴尔病毒阴性。CD79a在大多数肿瘤细胞中呈阳性,除了一小部分对CD3呈强阳性,但对其他T细胞标志物(CD2、CD5、CD7、CD4和CD8)及CD56呈阴性的区域。原始肿瘤的肿瘤性浆细胞CD3阴性。据我们所知,仅有一例复发性浆细胞瘤伴CD3异常表达的病例被报道,该病例显示复发时有疾病进展。然而,我们的病例中未观察到疾病进展的形态学证据。